This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



aciclovir lauriad (Sitavig®)


Reference No. 1501

Publication date:
01/08/2013


Appraisal information

aciclovir lauriad (Sitavig®) 50 mg buccal tablet


Company: BioAlliance Pharma
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, aciclovir lauriad (Sitavig®) cannot be endorsed for use within NHS Wales for the treatment of recurrent herpes labialis in immunocompetent adults with frequent herpes episodes.
Statement of Advice (SOA)
Download